Multiple Myeloma

• CLINICAL_TRIALS trial_result · 2019-08-02
  Clinical Trial Update: Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) [Phase 3]

  Phase 3 study of pomalidomide and low-dose dexamethasone with or without pembrolizumab in relapsed/refractory multiple myeloma was terminate…

• CLINICAL_TRIALS trial_result · 2019-07-17
  Clinical Trial Update: Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant [Phase 2]

  Phase 2 trial evaluating pembrolizumab with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients eligible for stem ce…

• CLINICAL_TRIALS trial_result · 2019-07-17
  Clinical Trial Update: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma [Phase 2]

  Phase 2 study evaluating oral ixazomib in combination with cyclophosphamide and dexamethasone for newly diagnosed or relapsed/refractory mul…

• CLINICAL_TRIALS trial_result · 2019-07-08
  Clinical Trial Update: Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma [Phase 2]

  Phase 2 clinical trial update for ixazomib-daratumumab without dexamethasone (IDara) in elderly patients with relapse-refractory multiple my…

• CLINICAL_TRIALS trial_result · 2019-07-02
  Clinical Trial Update: Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma [Phase 2]

  Phase 2 trial updating combination chemotherapy, peripheral stem cell transplant, biological therapy, pamidronate, and thalidomide in multip…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2019-06-28
  Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma [Phase 1]

  Phase 1 study of GSK2816126 in relapsed/refractory B-cell and solid tumor malignancies terminated; results posted in 2019.

• CLINICAL_TRIALS trial_result · 2019-06-26
  Clinical Trial Update: Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma [Phase 2]

  Phase 2 trial investigating nelfinavir as a drug to sensitize bortezomib in patients with myeloma not responding to proteasome inhibitors; s…

• CLINICAL_TRIALS trial_result · 2019-06-18
  Clinical Trial Update: Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 2]

  Phase 2 trial evaluating pomalidomide with cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma has completed.

• CLINICAL_TRIALS trial_result · 2019-06-10
  Clinical Trial Update: Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment [Phase 1]

  Phase 1 pharmacokinetics study of oral ixazomib (MLN9708) in relapsed/refractory multiple myeloma and advanced solid tumors, including parti…

• CLINICAL_TRIALS trial_result · 2019-06-04
  Clinical Trial Update: B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma [Phase 2]

  Phase 2 clinical trial update for BMCA-targeted CAR-T therapy in refractory/relapsed multiple myeloma.

• CLINICAL_TRIALS trial_result · 2019-06-04
  Clinical Trial Update: Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma [Phase 1, Phase 2]

  Phase 1/2 study evaluating a conditioning regimen of bendamustine and melphalan followed by transplant in patients with multiple myeloma; st…

• CLINICAL_TRIALS trial_result · 2019-06-03
  Clinical Trial Update: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) [Phase 2]

  Phase 2 trial evaluating pomalidomide and low-dose dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma complete…

• CLINICAL_TRIALS trial_result · 2019-05-31
  Clinical Trial Update: Study of MLN8237 in Participants With Advanced Hematological Malignancies [Phase 1]

  Phase 1 study of MLN8237 in advanced hematological malignancies completed; results posted in 2019.

• CLINICAL_TRIALS trial_result · 2019-05-30
  Clinical Trial Update: Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

  Phase 2 trial evaluating lenalidomide with nivolumab in relapsed or refractory multiple myeloma has been terminated; results posted in 2019.

• CLINICAL_TRIALS trial_result · 2019-05-29
  Clinical Trial Update: Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]

  Phase 2 clinical trial evaluating sonidegib and lenalidomide after stem cell transplant in patients with recurrent or refractory multiple my…

• CLINICAL_TRIALS trial_result · 2019-05-17
  Clinical Trial Update: Positron Emission Tomography (PET) Imaging Studies With NIS Reporter [Phase 1, Phase 2]

  A Phase 1/2 clinical trial investigating PET imaging with an NIS reporter in patients with myeloma and endometrial cancer; the study is term…

• CLINICAL_TRIALS trial_result · 2019-05-07
  Clinical Trial Update: A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant [Phase 3]

  Phase 3 study evaluating ixazomib citrate as maintenance therapy after autologous stem cell transplant in multiple myeloma; results have bee…

• CLINICAL_TRIALS trial_result · 2019-05-07
  Clinical Trial Update: Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM [Phase 1, Phase 2]

  Clinical trial update on adoptive BCMA CAR-NK cells for relapsed/refractory multiple myeloma across Phase 1 and Phase 2.

• CLINICAL_TRIALS trial_result · 2019-05-01
  Clinical Trial Update: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies [Phase 2]

  Phase 2 clinical trial evaluating BL-8040 for mobilizing donor hematopoietic stem cells to enable allogeneic transplantation in patients wit…

• CLINICAL_TRIALS trial_result · 2019-04-29
  Clinical Trial Update: Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) [NA]

  A terminated clinical trial evaluating thalidomide to overcome lenalidomide resistance after autologous stem cell transplantation in myeloma…

• CLINICAL_TRIALS trial_result · 2019-04-23
  Clinical Trial Update: Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

  Phase 1/2 trial evaluating ibritinib in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma; study term…

• CLINICAL_TRIALS trial_result · 2019-04-17
  Clinical Trial Update: Bortezomib Consolidation Trial [Phase 2]

  A Phase 2 clinical trial update evaluating bortezomib as consolidation therapy in multiple myeloma has completed.

• CLINICAL_TRIALS trial_result · 2019-04-08
  Clinical Trial Update: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

  Phase 1/2 trial evaluating carfilzomib with pegylated liposomal doxorubicin and dexamethasone in relapsed or refractory multiple myeloma has…

• CLINICAL_TRIALS trial_result · 2019-04-03
  Clinical Trial Update: A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma [Phase 2]

  Phase 2 trial evaluating Dara-CyBorD in previously untreated and relapsed multiple myeloma completed with results posted in 2019.

• CLINICAL_TRIALS trial_result · 2019-03-26
  Clinical Trial Update: Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma [Phase 2]

  Phase 2 trial evaluating adoptive cellular immunotherapy after autologous stem cell transplantation in multiple myeloma completed with poste…